Increased costs cannot be exclusively attributed to the consequences of insulin prescription. Any initiative designed to accelerate acquisition of patient autonomy would be likely to reduce the costs observed after switching to insulin, provided this initiative is adapted to the patient’s health profile, diabetes history and available medical resources..
[Determinants of the cost of initiation of insulin therapy type 2 diabetic patients in France: possible approaches to optimization].
Sante Publique. 2016;28(6):781-789.
MeSH terms: Aged; Costs and Cost Analysis; Diabetes Mellitus, Type 2; France; Humans; Hypoglycemic Agents; Infant; Insulin; Male; Middle Aged